<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0902221703
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        APO-DICLO 50 mg enteric-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Enteric-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- How APO-DICLO works:</strong></u></p><p>APO-DICLO (diclofenac sodium), as nonsteroidal anti-inflammatory drugs (NSAIDs), can reduce the chemicals prostaglandins produced by your body which cause pain and swelling. APO-DICLO, as nonsteroidal anti- inflammatory drugs (NSAIDs) do NOT cure your illness or prevent it from getting worse. APO-DICLO can only relieve pain and reduce swelling as long as you continue to take it.</p><p>&nbsp;</p><p><u><strong>b- What the medication is used for:</strong></u></p><p>Your health care provider has prescribed APO-DICLO for you to relieve pain and swelling in rheumatoid arthritis and osteoarthritis, including degenerative joint disease of the hip. APO-DICLO is used for maintenance therapy only</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not take APO-DICLO:</strong></u></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>Diclofenac is contraindicated in following conditions:</strong></p><p>a.&nbsp; Ischemic heart disease</p><p>b.&nbsp; Peripheral arterial disease</p><p>c.&nbsp; Cerebrovascular disease</p><p>d.&nbsp; Congestive heart failure (New York Heart Association [NYHA] classification II- IV)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>DO</strong><strong> </strong><strong>NOT</strong><strong> </strong><strong>TAKE APO-DICLO if you have any of the following medical conditions:</strong></p><ul><li>Heart bypass surgery (planning to have or recently had)</li><li>Severe, uncontrolled heart failure</li><li>Bleeding in the brain or other bleeding disorders</li><li>Current pregnancy (after 28 weeks of pregnancy)</li><li>Currently breastfeeding (or planning to breastfeed)</li><li>Allergy (hypersensitivity) to diclofenac sodium, or ASA (Acetylsalicylic Acid) or other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), or any of the nonmedicinal ingredients in APO-DICLO.</li><li>Ulcer (active)</li><li>Bleeding from the stomach or gut (active)</li><li>Inflammatory bowel disease (Crohn&rsquo;s Disease or Ulcerative Colitis)</li><li>Liver disease (active or severe)</li><li>Kidney disease (severe or worsening)</li><li>High potassium in the blood</li></ul><p>Patients who took a drug in the same class as APO-DICLO after a type of heart surgery (coronary artery bypass grafting (CABG)) were more likely to have heart attacks, strokes, blood clots in the leg(s) or lung(s), and infections or other complications than those who did NOT take that drug.</p><p>&nbsp;</p><p>APO-DICLO should NOT be used in patients under 16 years of age since the safety and effectiveness have NOT been established.</p><p>&nbsp;</p><p><u><strong>a- Warnings and precautions:</strong></u></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>&quot;Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (e.g. , hypertension, hyperlipidemia, diabetes mellitus, and smoking)&quot;.</p><p>&quot;As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically&quot;.</p></td></tr></tbody></table><p>&nbsp;</p><p>If you have, or previously had, any of the following medical conditions, see your health care provider to discuss treatment options other than APO-DICLO:</p><ul><li>Heart Attack or Angina</li><li>Stroke or Mini-stroke</li><li>Loss of Vision</li><li>Current Pregnancy (less than 28 weeks)</li><li>Congestive Heart Failure</li></ul><p>&nbsp;</p><p><strong>a-&nbsp;Take special care:</strong></p><p>Before taking this medication, tell your health care provider if you have any of the following:</p><ul><li>High blood pressure</li><li>High cholesterol</li><li>Diabetes mellitus or on a low sugar diet</li><li>Atherosclerosis</li><li>Poor circulation to your extremities</li><li>Smoker or ex-smoker</li><li>Kidney disease or urine problems</li><li>Previous ulcer or bleeding from the stomach or gut</li><li>Previous bleeding <strong>in</strong><strong> </strong>the brain</li><li>Bleeding problems</li><li>Family history of allergy to NSAIDs, such as acetylsalicylic acid (ASA), celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenic acid, tolmetin, or valdecoxib (NOT a complete list)</li><li>Family history of asthma, nasal polyps, long-term swelling of the sinus (chronic sinusitis) or hives.</li></ul><p>&nbsp;Also, before taking this medication, tell your health care provider if you are planning to get pregnant.</p><p><strong>Long-term use of APO-DICLO might increase the risk of heart attacks or strokes.</strong></p><p>&nbsp;</p><p><u><strong>b-Interactions with this medication:</strong></u></p><p>See your health care provider and pharmacist if you are taking any other medication (prescription or non- prescription) such as any of the following (NOT a complete list):</p><ul><li>Acetaminophen</li><li>Acetylsalicylic Acid (ASA) or other NSAIDs e.g. ASA, celecoxib, diclofenac, ibuprofen, indomethacin, ketorolac, meloxicam, naproxen</li><li>Alcohol</li><li>Antacids</li><li>Anti-depressants</li><li>Selective Serotonin Reuptake Inhibitors (SSRIs) e.g. citalopram, fluoxetine, paroxetine, sertraline</li><li>Blood pressure medications ACE (angiotensin converting enzyme) inhibitors e.g. enalapril lisinopril, perindopril, ramipril. ARBs (angiotensin II receptor blockers) e.g.candesartan, irbesartan, losartan, valsartan. Beta-blockers e.g. metoprolol.</li><li>Blood thinners (medicine used to prevent blood clotting) e.g. warfarin, ASA, clopidogrel</li><li>Corticosteroids (including glucocorticoids) (medicines used to provide relief for inflamed areas of the body) e.g. prednisone.</li><li>Cyclosporin or tacrolimus (a medicine primarily used in patients who have received organ transplants)</li><li>Digoxin (a medicine used for heart problems) Diuretics (medicines used to increase the amount of urine) e.g. furosemide, hydrochlorothiazide.</li><li>Lithium</li><li>Methotrexate ( a medicine used to treat some kinds of cancer or arthritis) Oral hypoglycemics (diabetes medications)</li><li>Probenecid</li><li>Quinolone antibacterials (medicines used against infection)</li></ul><p>&nbsp;</p><p>Your health care provider may prescribe low dose ASA (acetylsalicylic acid) as a blood thinner to reduce your risk of having a heart attack or stroke while you are taking APO-DICLO. Take only the amount of ASA prescribed by your health care provider. You are more likely to upset or damage you stomach if you take both APO-DICLO and ASA than if you took APO-DICLO alone.<br /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:372.5pt;height:151.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- <u>Usual dose:</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medical Condition</strong><strong> </strong><strong>(Age</strong><strong> Group)</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance</strong><strong> </strong><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Maximum Dose</strong><strong> (per day)*</strong></p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>APO-DICLO</strong><strong> 25 mg and 50 mg enteric coated tablets</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rheumatoid</strong><strong> </strong><strong>Arthritis</strong></p><p>(16 years of age and older)</p></td><td style="vertical-align:top"><p><strong>Maintenance</strong><strong> </strong><strong>dose</strong><strong> only:</strong></p><p>50 mg 2 times a day</p></td><td style="vertical-align:top"><p>100 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>Osteoarthritis</strong></p><p>(16 years of age and older)</p></td><td style="vertical-align:top"><p><strong>Maintenance</strong><strong> </strong><strong>dose</strong><strong> only:</strong></p><p>50 mg 2 times a day</p></td><td style="vertical-align:top"><p>100 mg</p></td></tr></tbody></table><p>* If your symptoms are not adequately controlled, you should contact your doctor, who may increase the total daily dose to a maximum of 150 mg in divided doses for a short period and with close monitoring. If you are older than 65 years, have liver problems, kidney problems, or heart problems, the maximum total dose per day should not exceed 100 mg of APO-DICLO (50 mg twice a day).</p><p>&nbsp;</p><p>Take APO-DICLO only as directed by your health care provider. <strong>Do NOT take more of it</strong>, <strong>do NOT take it more often and do NOT take it for a longer period of time than your health care provider recommended. If possible, you should take the lowest dose of this medication for the shortest time period. </strong>Taking too much APO-DICLO may increase your chances of unwanted and sometimes dangerous side effects, especially if you are elderly, have other diseases or take other medications.</p><p>Whether you have been prescribed oral tablets make sure that you do not take more than a total of 150 mg per day.</p><p>If you will be using APO-DICLO for more than 7 days, see your health care provider regularly to discuss whether this medicine is working for you and if it is causing you any unwanted effects.</p><p>&nbsp;</p><p><strong>APO-DICLO</strong><strong> </strong><strong>(enteric coated tablets):</strong></p><p>APO-DICLO tablets are an extended release product. <strong>Tablets should be swallowed whole with water and must not be divided or chewed.</strong></p><p>To help reduce the possibility of stomach upset you should take APO-DICLO tablets immediately after a meal or &nbsp;with food or milk. Also, you should remain standing or sitting upright (i.e. do not lie down) for about 15-30 minutes after taking the medicine. This helps to prevent irritation that may lead to trouble swallowing. If stomach upset (indigestion, nausea, vomiting, stomach pain or diarrhea) occurs and continues, contact your doctor</p><p><strong>This</strong><strong> </strong><strong>medication has been prescribed specifically for you. Do NOT give it to anyone else. It may harm them, even if their symptoms seem to be similar to yours.</strong></p><p><strong>APO-DICLO</strong><strong> </strong><strong>is</strong><strong> </strong><strong>NOT</strong><strong> </strong><strong>recommended for use in patients under 16 years of age since safety and effectiveness have NOT been established.</strong></p><p><strong>&nbsp;</strong></p><p><u><strong>b-If you take more APO-DICLO than should:</strong></u></p><p>If you have accidentally taken more than the prescribed dose of APO-DICLO tablets <strong>contact your doctor, pharmacist or poison control centre immediately, or go to the hospital emergency unit at once. </strong>You may require medical attention.</p><p>&nbsp;</p><p><u><strong>c-&nbsp;If you forget to take APO-DICLO</strong></u></p><p>If you forget to take one or more doses of APO-DICLO (diclofenac sodium) 25 mg and 50 mg tablet, you should not increase the dose of APO-DICLO (diclofenac sodium) to make up for the missed dose or doses, but you should continue taking your tablet at the next prescribed or regular time.</p><p>&nbsp;</p><p><strong><u>While</u></strong><strong><u> </u></strong><strong><u>taking this medication</u></strong>:</p><ul><li>tell any other doctor, dentist, pharmacist or other health care professional that you see, that you are taking this medication, especially if you are planning to have heart surgery;</li><li>do NOT drink alcoholic beverages while taking this medication because you would be more likely to develop stomach problems;</li><li>fertility may be decreased. The use of APO-DICLO is not recommended in women trying to get pregnant. In women who have difficulty conceiving, stopping APO-DICLO should be considered.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>APO-DICLO may cause some side effects, especially when used for a long time or in large doses. When these side effects occur, you may require medical attention. Report all symptoms or side effects to your health care provider.</p><p>APO-DICLO may cause you to become drowsy or tired. Be careful about driving or participating in activities that require you to be alert. If you become drowsy, dizzy or light-headed after taking APO-DICLO, do NOT drive or operate machinery.</p><p>APO-DICLO may cause you to become more sensitive to sunlight. Any exposure to sunlight or sunlamps may cause sunburn, skin blisters, skin rash, redness, itching or discolouration, or vision changes. If you have a reaction from the sun, check with your health care provider.</p><p>Check with your health care provider IMMEDIATELY if you develop chills, fever, muscle aches or pains, or other flu-like symptoms, especially if they occur before or together with a skin rash. These symptoms may be the first signs of a SERIOUS ALLERGIC REACTION to this medication.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="3"><p><strong>SERIOUS</strong><strong> </strong><strong>SIDE</strong><strong> </strong><strong>EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td style="vertical-align:top; width:555px"><p><strong>Symptom / effect</strong></p></td><td style="vertical-align:top; width:177px"><p><strong>STOP taking APO-DICLO and get emergency medical attention IMMEDIATELY</strong></p></td><td style="vertical-align:top; width:141px"><p><strong>STOP taking APO-DICLO and talk to your physician or pharmacist</strong></p></td></tr></tbody></table><table style="width:875px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:555px"><p>Bloody or black tarry stools</p></td><td style="vertical-align:top; width:176px"><p>✔</p></td><td style="vertical-align:top; width:141px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Shortness of breath, wheezing, any trouble breathing or chest tightness</p></td><td style="vertical-align:top; width:176px"><p>✔</p></td><td style="vertical-align:top; width:141px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Skin rash, hives, swelling or itching</p></td><td style="vertical-align:top; width:176px"><p>✔</p></td><td style="vertical-align:top; width:141px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Blurred vision, or any visual disturbance</p></td><td style="vertical-align:top; width:176px"><p>✔</p></td><td style="vertical-align:top; width:141px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Any change in the amount or colour of your urine (red or brown)</p></td><td style="vertical-align:top; width:176px"><p>✔</p></td><td style="vertical-align:top; width:141px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Any pain or difficulty experienced while urinating</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Swelling of the feet, lower legs; weight gain</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Vomiting or persistent indigestion, nausea, stomach pain or diarrhea</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Yellow discolouration of the skin or eyes (signs of liver failure), with or without itchy skin</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Malaise, fatigue, loss of appetite</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Headaches, stiff neck</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Mental confusion, depression</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Dizziness, lightheadedness</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Hearing problems</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Rectal itching or bleeding</p></td><td style="vertical-align:top; width:176px"><p>&nbsp;</p></td><td style="vertical-align:top; width:141px"><p>✔</p></td></tr></tbody></table><p><strong>This</strong><strong> </strong><strong>is</strong><strong> </strong><strong>NOT a complete list of side effects. For any unexpected effects or any other symptom while taking APO-DICLO, contact your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><strong>Keep medicaments out of the reach of children.</strong></li><li><strong>Do NOT keep outdated medicine or medicine no longer needed. </strong>Any outdated or unused medicine should be returned to your pharmacist.</li><li>APO-DICLO should be stored below 25&deg; C.</li><li>APO-DICLO should be protected from high humidity.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a-What the medicinal ingredient is</u></strong></p><p>APO-DICLO 50 mg enteric coated tablets, each tablet containing 50 mg Diclofenac Sodium.</p><p>&nbsp;</p><p><strong>b-<u>What the important nonmedical ingredients are</u>&nbsp;</strong></p><p>Each enteric coated tablet contains the non-medicinal ingredients:</p><p>dextrates, methylcellulose, stearic acid, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, FD &amp; C yellow #6, polyvinylacetate phthalate, triethyl citrate and methanol.</p><p>Each 25 mg tablet also contains the nonmedicinal ingredient D&amp;C yellow #10.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                APO-DICLO 25 mg (enteric coated): yellow, round, identified ‘25’ on one side.

APO-DICLO 50 mg (enteric coated): light brown, round, identified ‘50’ on one side. Check with your pharmacist if the identifying markings or color appear different.  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in 02/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>أ- كيفية عمل الدواء ابو-ديكلو:</strong><br />ينتمي ابو-ديكلو (ديكلوفيناك صوديوم) إلى فئة مضادات الالتهابات غير الستيرويدية، ويعمل على خفض البروستاجلاندينات الكيميائية التي ينتجها الجسم والتي تسبب الألم والتورم. وحيث إن العقار ابو-ديكلو من مضادات الالتهاب غير الستيرويدية؛ فإنه لا يحقق الشفاء التام للمرض ولا يمنع تفاقمه. وإنما يعمل هذا العقار على تخفيف الألم وتقليل التورم ما دمت تستخدمه.</p><p><br /><strong>ب- دواعي استخدام هذا الدواء:</strong><br />لقد وصف لك الطبيب العقار ابو-ديكلو لتخفيف الألم والتورم المصاحبين لحالات التهاب المفاصل الروماتويدي والتهاب المفاصل، بما في ذلك مرض المفاصل التنكسية في الورك. ويسُتخدم هذا العقار لعلاج الصيانة فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا يؤخذ ابو-ديكلو في الحالات التالية:</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>ديكلوفيناك يتعارض مع الحالات الآتية:</p><ul><li dir="rtl">مرضى نقص تروية القلب</li><li dir="rtl">مرضى الشرايين الطرفية</li><li dir="rtl">الأمراض الدماغية الوعائية</li><li dir="rtl">قصور القلب الاحتقاني التصنيف الثاني إلى الرابع [NYHA] (جمعية القلب في نيويورك)</li></ul></td></tr></tbody></table><p><strong>لا تأخذ ابو-ديكلو إذا كنت تعاني من أيٍ من الحالات المرضية التالية:</strong></p><ul><li>جراحة تغيير شرايين القلب (أو تخطط لها أو أجُريت لك بالفعل مؤخرًا)</li><li>فشل قلب حاد غير خاضع للسيطرة</li><li>نزيف في المخ أو اضطرابات نزفية أخرى</li><li>الحمل (بعد الأسبوع ۲۸ من الحمل)</li><li>الرضاعة الطبيعية (أو التخطيط لها)</li><li>الحساسية (فرط الحساسية) لمادة ديكلوفيناك الصوديوم، أو حمض اسيتيل سالسيلك أو مضادات الالتهاب غير الستيرويدية الأخرى أو أيٍ من المكونات غير الدوائية في العقار ابو-ديكلو.</li><li>القرحة (النشطة)</li><li>مزيف المعدة أو الأمعاء (في حالة نشطة)</li><li>مرض التهاب الأمعاء (مرض كرون أو التهاب القولون التقرحي)</li><li>أمراض الكبد ( في حالة نشطة أو شديدة)</li><li>أمراض الكلى (في حالة شديدة أو متفاقمة)</li><li>زيادة البوتاسيوم في الدم</li></ul><p>المرضى الذين تناولوا دواءً من فئة ابو-ديكلو كانوا أكثر عرضة للإصابة بنوبات قلبية وسكتات دماغية وجلطات في الساق بعد إجراء نوع من عمليات جراحية في القلب (طعُم مجازة الشريان التاجي (CABG)) أو الرئة، والتهابات أو مضاعفات أخرى - مقارنة بالمرضى الذين لم يتناولوا&nbsp; ذلك الدواء.</p><p>يجب عدم استخدام ابو-ديكلو في المرضى تحت سن ۱٦ سنة حيث إنه لم يتم التأكد من فعالية وسلامة استخدام هذا العقار.</p><p>&nbsp;</p><p><strong>ب-التحذيرات والاحتياطات:</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>يجب فقط أن يبدأ العلاج بديكلوفيناك بعد دراسة متأنية للمرضى الذين يعانون من<br />عوامل خطر كبير لأحداث القلب والأوعية الدموية مثل ارتفاع ضغط الدم، ارتفاع<br />الدهون، داء السكري و التدخين.<br />كما أن مخاطر القلب والأوعية الدموية قد تزيد مع الجرعة ومدة التعرض من<br />ديكلوفيناك ، وينبغي استخدام أقصر مدة ممكنة وبأقل جرعة يومية فعالة. كذلك حاجة<br />المريض لتخفيف الأعراض واستجابة للعلاج يجب إعادة تقييمها بشكل دوري.</td></tr></tbody></table><p>&nbsp;</p><p>إذا كنت تعاني حالياً - أو سابقًا - من الحالات الطبية التالية، فينبغي استشارة طبيبك لمناقشة خيارات العلاج الأخرى غير<br />العقارين ابو-ديكلو:</p><ul><li>نوبات قلبية أو ذبحة صدرية</li><li>سكتة دماغية أو سكتة دماغية صغيرة</li><li>فقدان الرؤية</li><li>الحمل (أقل من ۲۸ أسبوعًا)</li><li>فشل القلب الاحتقاني</li></ul><p><strong>ج- اتخاذ العناية الخاصة:</strong><br />قبل تناول هذا الدواء؛ أخبر طبيبك إذا كنت تعاني من أيٍ من الحالات التالية:</p><ul><li>ارتفاع ضغط الدم</li><li>ارتفاع الكوليسترول</li><li>الداء السكري أو اتباع نظام غذائي منخفض السكر</li><li>التصلب العصيدي للشرايين</li><li>ضعف الدورة الدموية في الأطراف</li><li>التدخين حاليًا أو التدخين سابقًا</li><li>مرض كلوي أو مشكلات في التبول</li><li>قرحة سابقة أو نزيف من المعدة أو الأمعاء</li><li>نزيف سابق في المخ</li><li>مشكلات نزفية</li><li>تاريخ عائلي من الحساسية لمضادات الالتهاب غير الستيرويدية، مثل حمض أسيتيل الساليسيليك، السيليكوكسيب، ديكلوفيناك، ثنائي الفلونيزال، إيتودولاك، فينوبروفين، فلوربيبروفين، ايبوبروفين اندوميثاسين، كيتوبروفين، كيتورولاك، حمض الميفيناميك، ميلوكسيكام، نابوميتون، نابروكسين، أوكسابروزين، بيروكسيكام، روفيكوكسيب، سولينداك، تينوكسيكام، حمض تيابروفيناك، تولميتين، أو فالديكوكسيب (وليست هذه قائمة كاملة بتلك الفئة من الأدوية)</li><li>تاريخ عائلي من الربو، البوليبات الأنفية (نوع من التهابات الأنف)، التهاب الجيوب الأنفية طويل المدى (التهاب الجيوب الأنفية المزمن) أو الشرى</li></ul><p>كما ينبغي للمريضة الأنثى التي تخطط للحمل إخبار الطبيب بهذه النية قبل تناول هذه الدواء.<br />قد يؤدى استخدام العقار ابو-ديكلو لمدة طويلة إلى زيادة احتمال الإصابة بنوبات قلبية أو سكتات دماغية.</p><p><strong>د- التفاعلات مع الأدوية الأخرى:</strong><br />ينبغي استشارة الطبيب والصيدلي إذا كنت تتناول أي أدوية أخرى (سواء التي تأخذها بوصفة طبية أو بدون وصفة طبية)<br />مثل أيٍ من الأدوية التالية (على سبيل المثال لا الحصر):</p><ul><li>أسيتامينوفين</li><li>حمض أسيتيل الساليسيليك أو مضادات الالتهاب غير الستيروئيدية الأخرى مثل السيليكوكسيب، ديكلوفيناك،</li><li>ايبوبروفين اندوميثاسين، كيتورولاك، ميلوكسيكام، نابروكسين</li><li>الكحول</li><li>مضادات الحموضة</li><li>مضادات الاكتئاب</li><li>مثبطات امتصاص السيروتونين الانتقائية على سبيل المثال سيتالوبرام، فلوكستين، باروكسيتين، سيرترالين</li><li>أدوية ضغط الدم: مثبطات الإنزيم المحوِّل للأنجيوتنسين مثل إنالابريل، ليسينوبريل، بيرندوبريل، راميبريل. مضادات مستقبلات الأنجيوتنسين ۲ مثل كاندسارتان، اربسارتان، لوسارتان فالسارتان. حاصرات بيتا مثل ميتوبرولول.</li><li>العقاقير المسيلة للدم (أدوية تسُتخدم لمنع تخثر الدم) مثل الوارفارين، حمض أسيتيل سالسيلك، كلوبيدوجرل</li><li>الستيرويدات القشرية (بما في ذلك السكرية) (أدوية مستخدمة لعلاج التهابات الجسم) على سبيل المثال بريدنيزون.</li><li>السيكلوسبورين أو تاكروليماس (دواء يسُتخدم في المقام الأول في المرضى الذين أجُريت لهم عمليات زرع أعضاء)</li><li>ديجوكسين (دواء يسُتخدم لعلاج بعض اضطرابات القلب)، مدرات البول (أدوية مستخدمة لزيادة كمية البول) على سبيل المثال فوروسيميد، هيدروكلوروثيازيد.</li><li>الليثيوم</li><li>ميثوتريكسيت (دواء يسُتخدم لعلاج بعض أنواع السرطان أو التهاب المفاصل)، أدوية نقص سكر الدم التي تؤخذ عن&nbsp;طريق الفم (أدوية السكري)</li><li>بروبنيسيد</li><li>المضادات الحيوية من فئة كينولون (أدوية تسُتخدم لعلاج العدوى البكتيرية)</li></ul><p>قد يصف لك الطبيب جرعة منخفضة من حمض الاستيل سالسيلك كعقار مسيِّل للدم للحد من خطر الإصابة بنوبة قلبية أو سكتة دماغية أثناء استخدامك للعقار ابو-ديكلو. وينبغي الالتزام بتناول الجرعة التي حددها لك الطبيب من حمض الاستيل سالسيلك بالضبط. إن تناول جرعات من العقار ابو-ديكلو مع جرعات من حمض الاستيل سالسيلك يزيد من احتمال اضطراب المعدة أو تضررها بدرجة أكبر من استخدام العقار ابو-ديكلو فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- الجرعة العادية:</strong></p><table style="width:551px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><strong>الحالة الطبية (الفئة العمرية)</strong></td><td style="width:139px"><strong>جرعة الصيانة</strong></td><td style="width:178px"><strong>الجرعة القصوى (في<br />اليوم)*</strong></td></tr><tr><td style="text-align:center" colspan="3">ابو-ديكلو ۲٥ ملجم و ٥۰ ملجم أقراص مغلفة معوياً</td><td colspan="3">&nbsp;</td></tr><tr><td>التهاب المفاصل الروماتويدي<br />(۱٦ سنة فما فوق)</td><td style="width:139px">جرعة الصيانة فقط:<br />٥۰ ملجم مرتين يومياً</td><td style="width:178px">۱۰۰ ملجم</td></tr><tr><td>التهاب المفاصل<br />(۱٦ سنة فما فوق)&nbsp;</td><td style="width:139px">جرعة الصيانة فقط:<br />٥۰ ملجم مرتين يومياً</td><td style="width:178px">۱۰۰ ملجم</td></tr></tbody></table><p>* إذا كانت الأعراض التي تعاني منها لا تخضع للسيطرة بشكل كاف، فيجب عليك الاتصال بالطبيب، الذي قد يزيد من الجرعة اليومية إلى حد أقصى قدره ۱٥۰ ملجم مقسمة على جرعات لفترة قصيرة مع الملاحظة الدقيقة لحالتك. إذا كان عمرك أكبر من ٦٥ سنة، أو تعاني من اضطرابات في الكبد أو في الكلى أو في القلب، فينبغي ألا تتجاوز الجرعة القصوى لكل يوم ۱۰۰ ملجم من ابو-ديكلو ( ٥۰ ملجم مرتين في اليوم).</p><p>لا تأخذ جرعات ابو-ديكلو إلا كما وصف لك الطبيب تمامًا. لا تأخذ جرعات كبيرة, ولا تأخذ جرعات بشكل متكرر ولا تستمر في تناول العقار لمدة أطول من التي حددها لك الطبيب. إن أمكن، ينبغي أن تأخذ أقل جرعة من هذا العقار لأقصر مدة ممكنة. إن تناول جرعات مفرطة من العقار ابو-ديكلو قد يزيد من احتمال حدوث آثار جانبية غير مرغوب فيها وخطيرة في بعض الأحيان، خاصة إذا كنت من كبار السن، أو تعاني من أمراض أخرى أو تأخذ أدوية أخرى.<br />إذا كان الطبيب قد وصف لك تناول قراص عن طريق الفم؛ فينبغي الحرص على عدم تناول جرعة أكثر من ۱٥۰ ملجم في اليوم.</p><p>&nbsp;</p><p>إذا كنت ستستخدم ابو-ديكلو لأكثر من ۷ أيام، فينبغي زيارة الطبيب بانتظام لمناقشة ما إذا كان هذا الدواء مفيد بالنسبة لك، وإذا كان يسبب لك أي آثار غير مرغوب فيها.</p><p><strong>ابو-ديكلو (أقراص ذات كسوة معوية):</strong><br />ابو-ديكلو أقراص عبارة عن منتج دوائي ممتد المفعول. ينبغي ابتلاع الأقراص كاملة، ولا يجب تقسيمها أو مضغها.<br />للحد من احتمال حدوث اضطراب في المعدة؛ ينبغي تناول أقراص ابو-ديكلو بعد تناول وجبة مباشرة أو أثناء الأكل أو الشرب. ينبغي أيضًا الوقوف أو الجلوس منتصباً (عدم الاضطجاع) لمدة 15-30&nbsp;دقيقة بعد تناول الأقراص. يساعد&nbsp;هذا على الوقاية من حدوث تهيج قد يؤدي صعوبة في البلع. إذا حدث اضطراب في المعدة (عسر هضم، غثيان، تقيؤ، ألم في المعدة أو إسهال) واستمر، يجب الاتصال بالطبيب.</p><p><br />هذا الدواء موصوف لك على وجه الخصوص. فلا تعطِ هذا الدواء إلى أي شخص آخر. قد يضر هذا الدواء الآخرين حتى لو<br />كانوا يعانون من أعراض مثل التي تعاني منها.</p><p><br />يجب عدم استخدام ابو-ديكلو في المرضى تحت سن ۱٦ سنة حيث إنه لم يتم التأكد من فعالية وسلامة استخدام هذين العقارين<br />في هذه الفئة العمرية.</p><p>&nbsp;</p><p><strong>ب- في حالة تناول جرعة زائدة من ابو-ديكلو:</strong><br />في حالة تناول جرعة زائدة عن الجرعة التي تحتاج إليها من أقراص ابو-ديكلو <strong>اتصل على الفور بالطبيب أو بمركز مكافحة السموم لديك أو قسم الطوارئ بالمستشفى. </strong>قد تحتاج إلى رعاية طبية.</p><p><br /><strong>ج- في حال لم تتناول جرعة ابو-ديكلو:</strong><br />في حالة نسيان تناول جرعة واحدة أو أكثر من أقراص ابو-ديكلو (ديكلوفيناك صوديوم) ۲٥ ملجم و ٥۰ ملجم، ينبغي عدم زيادة الجرعة لتعويض الجرعة أو الجرعات الفائتة، ولكن ينبغي الاستمرار في تناول الأقراص في الوقت المحدد للجرعة التالية الموصوفة لك.</p><p><br /><strong>د- اثناء تناول هذا الدواء:</strong></p><ul><li>أخبر أي أطباء آخرين أو أطباء أسنان أو صيادلة تذهب إليهم للعلاج أنك تأخذ هذا الدواء؛ خصوصًا إذا كنت ستخضع لجراحة في القلب؛</li><li>لا تشرب مشروبات كحولية أثناء استخدام هذا الدواء لأنك ستكون أكثر عرضة للإصابة باضطرابات في المعدة؛</li><li>قد تنخفض الخصوبة. لا يوصى باستخدام ابو-ديكلو في النساء اللاتي يرغبن في الحمل. في حالة النساء اللاتي يعانين من صعوبة في حدوث حمل؛ ينبغي التفكير في التوقف عن تناول ابو-ديكلو.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب ابو-ديكلو بعض الآثار الجانبية خصوصًا عند استخدامه لمدة طويلة أو تناول جرعات كبيرة منه. عند حدوث هذه الآثار الجانبية؛ قد تحتاج إلى عناية طبية. ينبغي إخبار الطبيب بجميع الأعراض أو الآثار الجانبية التي تحدث لديك.</p><p>قد يؤدي تناول ابو-ديكلو إلى إصابتك بالنعاس أو التعب. ينبغي توخي الحذر عند قيادة المركبات أو المشاركة في أنشطة تتطلب اليقظة والانتباه. في حالة شعورك بالنعاس أو الدوار أو الدوخة بعد تناول ابو-ديكلو؛ لا تقم بقيادة مركبات أو تشغيل آلات.</p><p>قد يؤدي تناول ابو-ديكلو إلى إصابتك بحساسية لضوء الشمس. قد يؤدي تعرضك لضوء الشمس أو المصابيح الشمسية إلى إصابتك بحروق أو تنفط في الجلد أو طفح جلدي أو احمرار أو حكة أو تغير لون الجلد أو تغيرات في الرؤية. إذا كنت تعاني من حساسية من ضوء الشمس؛ فينبغي استشارة الطبيب.<br />ينبغي استشارة الطبيب على الفور إذا شعرت بقشعريرة أو حمى أو ألم في العضلات أو آلام أخرى أو أعراض مشابهة للأنفلونزا؛ خصوصًا حال حدوثها قبل طفح جلدي أو معه. قد تكون هذه الأعراض هي العلامات الأولى على رد فعل تحسسي خطير لهذا الدواء.</p><p>&nbsp;</p><table style="width:843px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:center; width:840px" colspan="3"><strong>الآثار الجانبية الخطيرة، ومدى تكرارها وكيفية التعامل معها</strong></td></tr><tr><td style="width:537px"><strong>العرض/الأثر</strong></td><td style="width:153px"><p><strong>ينبغي التوقف عن تناول ابو-ديكلو<br />والحصول على العناية الطبية الفورية.</strong></p></td><td style="width:151px"><strong>ينبغي التوقف عن تناول ابو-ديكلو واستشارة الطبيب<br />أو الصيدلي.</strong></td></tr><tr><td style="width:537px">براز دموي أو أسود قطراني</td><td style="width:153px">✔</td><td style="width:151px">&nbsp;</td></tr><tr><td style="width:537px">قصر النفس، أزيز، أي مشكلة في التنفس أو ضيق في الصدر</td><td style="width:153px">✔</td><td style="width:151px">&nbsp;</td></tr><tr><td style="width:537px">طفح جلدي، شرى، تورم أو حكة</td><td style="width:153px">✔</td><td style="width:151px">&nbsp;</td></tr><tr><td style="width:537px">تشوش الرؤية، أو أي اضطراب في الرؤية</td><td style="width:153px">✔</td><td style="width:151px">&nbsp;</td></tr><tr><td style="width:537px">أي تغير في كمية أو لون البول (أحمر أو بني)</td><td style="width:153px">✔</td><td style="width:151px">&nbsp;</td></tr><tr><td style="width:537px">أي ألم أو صعوبة في التبول</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">تورم القدمين أو الجزء السفلي من الرجلين أو زيادة الوزن</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">القيء أو عسر الهضم المستمر، الغثيان، آلام في المعدة أو إسهال</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">اصفرار الجلد أو العينين (علامات فشل الكبد)، مع حكة في الجلد أو بدونها</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">توعك، تعب، فقدان الشهية</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">صداع، تصلب الرقبة</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">ارتباك ذهني، اكتئاب</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">دوار، دوخة</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">مشكلات في السمع</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr><tr><td style="width:537px">حكة شرجية أو نزيف شرجي</td><td style="width:153px">&nbsp;</td><td style="width:151px">✔</td></tr></tbody></table><p><strong>وهذه ليست قائمة كاملة بكل الآثار الجانبية. في حالة حدوث أي آثار غير متوقعة أو أي أعراض أثناء تناول ابو-ديكلو؛ ينبغي الاتصال بالطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</li><li>لا تحتفظ بالأدوية منتهية الصلاحية أو التي لا تحتاج إليها. ينبغي إعادة أي أدوية منتهية الصلاحية أو غير مستخدمة إلى الصيدلي.</li><li>ينبغي تخزين ابو-ديكلو في درجة حرارة أقل من ۲٥ درجة مئوية.</li><li>ينبغي حماية ابو-ديكلو من الرطوبة العالية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- ما مكونات هذا الدواء؟</strong><br />ابو-ديكلو ٥۰ ملجم أقراص مغلفة معوي اً، كل قرص يحتوي على ٥۰ ملجم ديكلوفيناك صوديوم.</p><p><br /><strong>ب- ما المكونات غير الطبية المهمة؟</strong><br />يحتوي كل قرص مغلف معوي اً على المكونات غير الطبية التالية:<br />دكسترات، ميثيل سيلولوز، حامض دهني، ستيرات المغنيسيوم، ثاني أكسيد السيليكون الغروي، هيدروكسي بروبيل ميثيل سيلولوز، بولي ايثيلين جلايكول، ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر، اف دي اند سي الأصفر رقم ٦ (معيار الأغذية والعقاقير ومستحضرات التجميل)، خلات الفينيل الفثالات، سيترات ثلاثي إيثيل وميثانول. يحتوي كل قرص تركيزه ۲٥ ملجم المكون غير الطبي &quot;دي اند سي&quot; أصفر رقم ۱۰.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ابو-ديكلو ۲٥ ملجم (أقراص مغلفة معوياً): صفراء مستديرة منقوش على أحد جانبي القرص رقم &quot; ۲٥&quot;</p><p>ابو-ديكلو ٥۰ ملجم (أقراص مغلفة معوي اً): لونها بني فاتح مستديرة منقوش على أحد جانبي القرص رقم &quot; ٥۰&quot;</p><p>ارجع إلى الصيدلي إذا كان هناك اختلاف في علامات تمييز الأقراص أو الألوان المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>أبوتكس إنك، تورنتو، أونتاريو، ام ۹ ال ۱تي ۹ كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة بتاريخ 02/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apo-Diclo
Diclofenac Sodium Enteric Coated Tablets 25 and 50 mg

Apo-Diclo  SR
Diclofenac Sodium Slow Release Tablets 75 and 100 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-DICLO (diclofenac sodium) Tablets 25 mg: round, biconvex, yellow, enteric-coated tablets, engraved '25' on one side.

APO-DICLO (diclofenac sodium) Tablets  50 mg: round, biconvex, light brown, enteric-coated tablets, engraved '50' on one side.

APO-DICLO SR (diclofenac sodium) Slow-Release Tablets 75  mg:   triangular,  light  pink, biconvex with bevelled edge, film-coated tablets, engraved 'APO' over '75' on one side, other side plain.

APO-DICLO  SR (diclofenac  sodium)  Slow-Release Tablets 100  mg:  round,  pink, biconvex with bevelled edge, film-coated tablets, engraved 'APO' over '100' on one side, other side plain.

Composition:

Enteric-Coated Tablets:  In addition to diclofenac sodium, each enteric coated tablet contains the non-medicinal ingredients dextrates, methylcellulose,  stearic acid, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, polyethylene  glycol, titanium dioxide, yellow ferric oxide, FD & C yellow #6, polyvinylacetate  phthalate, triethyl citrate and methanol. Each 25 mg tablet also contains the non-medicinal  ingredient D&C yellow #10.

Slow-Release Tablets:  In addition to diclofenac sodium, each slow release  tablet contains the non- medicinal ingredients dextrates, microcrystalline  cellulose, hydroxyethyl cellulose, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and red ferric oxide.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-DICLO (diclofenac sodium) Tablets 25 mg: round, biconvex, yellow, enteric-coated tablets, engraved '25' on one side. available in bottles of 100, 500 and 1000 tablets and 30 tablets blister.
 
APO-DICLO (diclofenac sodium) Tablets  50 mg: round, biconvex, light brown, enteric-coated tablets, engraved '50' on one side. available in bottles of 100, 500 and 1000 tablets and 20 tablets blister.

APO-DICLO SR (diclofenac sodium) Slow-Release Tablets 75  mg:   triangular,  light  pink, biconvex with bevelled edge, film-coated tablets, engraved 'APO' over '75' on one side, other side plain. available in bottles of 100, 500 and 1000 tablets.

APO-DICLO  SR (diclofenac  sodium)  Slow-Release Tablets 100  mg:  round,  pink, biconvex with bevelled edge, film-coated tablets, engraved 'APO' over '100' on one side, other side plain. available in bottles of 100, 500 and 1000 tablets and 10 tablets blister.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-DICLO (diclofenac sodium) and APO-DICLO SR (diclofenac sodium) are indicated for the following:</p><ul><li>the symptomatic treatment of rheumatoid arthritis and osteoarthritis, &nbsp;including degenerative &nbsp;joint disease of the hip.</li></ul><p>&nbsp;</p><p><em>Throughout this document, the term NSAIDs refers to both non-selective NSAIDs and selective&nbsp;COX-2 inhibitor NSAIDs, unless otherwise indicated.</em></p><p><strong>For &nbsp;patients with an increased risk of &nbsp;developing CV &nbsp;and/or Gl adverse events, other management strategies that do NOT include the &nbsp;use of NSAIDs &nbsp;should be &nbsp;considered first. (See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS)</strong></p><p><strong>Use of APO-DICLO or APO-DICLO SR should be limited to the lowest effective dose for&nbsp;the&nbsp;&nbsp;shortest possible duration of &nbsp;treatment in order to &nbsp;minimize the &nbsp;potential risk for&nbsp;cardiovascular&nbsp;or &nbsp;gastrointestinal &nbsp;adverse events. (See &nbsp;CONTRAINDICATIONS and&nbsp;WARNINGS&nbsp;AND&nbsp;PRECAUTIONS)</strong></p><p><strong>&nbsp;</strong></p><p>APO-DICLO and APO-DICLO SR, as NSAIDs, do NOT treat clinical disease or prevent its progression.</p><p>APO-DICLO and APO-DICLO SR, as NSAIDs, only relieve symptoms and decrease inflammation for as long as the patients continues to take them.</p><p>&nbsp;</p><p><strong><em>Patients Subsets</em></strong></p><p><em>Geriatrics</em></p><p>Evidence &nbsp;from clinical &nbsp;studies &nbsp;and &nbsp;post-market &nbsp;experience &nbsp;suggests &nbsp;that use &nbsp;in the &nbsp;geriatric population is associated with differences in safety (See WARNINGS &nbsp;AND PRECAUTIONS).</p><p>&nbsp;</p><p><em>Pediatrics&nbsp;(&lt;16&nbsp;years&nbsp;of age)</em></p><p>Safety and efficacy have not been established in the pediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><strong>Dosing Considerations</strong></em></p><p><em>Geriatrics: </em>For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision. (See WARNINGS AND PRECAUTIONS _special Populations <em>Geriatrics)</em></p><p><em>&nbsp;</em></p><p><em>Renal Insufficiency: </em>Lower doses of APO-DICLO or APO-DICLO SR should be considered in patients with impaired renal function. (see WARNINGS AND PRECAUTIONS -Renal)</p><p>&nbsp;</p><p><em>Hepatic Impairment: </em>Lower doses of APO-DICLO or APO-DICLO SR should be considered in patients with impaired hepatic function. (see WARNINGS AND PRECAUTIONS _ Hepatic/Biliary/Pancreatic)</p><p>&nbsp;</p><p><em><strong>Recommended Dose and Dose Adjustment</strong></em></p><p>APO-DICLO and APO-DICLO SR are to be used for maintenance therapy only.</p><p>As a general recommendation, the dose should be individually adjusted and the lowest effective dose given for the shortest possible duration.</p><p>&nbsp;</p><p><strong>APO-DICLO Tablets 25 mg and 50 mg (enteric-coated)</strong></p><p>Rheumatoid arthritis and osteoarthritis patients may use APO-DICLO (diclofenac sodium) enteric-coated tablets if:</p><ul><li>They were previously initiated at the lowest dose of 75 mg (enteric-coated) per day in 3 divided doses and required up-titration because they did not respond to that dose.</li><li>The maximum recommended daily dose is 100 mg.</li><li>For patients experiencing an inflammatory flare, who do not achieve control of symptoms with 100 mg of diclofenac, the dosage may be increased to a maximum of 150 mg per day in divided doses (50 mg TID), for the shortest possible duration and under close monitoring (See WARNINGS and PRECAUTIONS- Cardiovascular).</li><li>In elderly patients, and patients with renal insufficiency, hepatic impairment or with a cardiovascular risk, the maximum daily dose should not exceed 100 mg of diclofenac (see Dosing Considerations).</li><li>APO-DICLO should be taken with food and the tablets should be swallowed whole.</li></ul><p>&nbsp;</p><p><strong>APO-DICLO SR 75 mg and 100 mg (slow-release tablets)</strong></p><ul><li>Patients with rheumatoid arthritis or osteoarthritis on a maintenance dose of 75 mg diclofenac sodium per day may be changed to a once daily dose of APO-DICLO SR 75 mg administered morning or evening.</li><li>Patients on a maintenance dose of 100 mg diclofenac sodium per day may be changed to a once daily dose of APO-DICLO SR 100 mg, administered morning or evening.</li><li>The maximum recommended daily dose is 100 mg.</li><li>For patients experiencing an inflammatory flare, who do not achieve control of symptoms with 100 mg of diclofenac, the dosage may be increased to a maximum of 150 mg per day in divided doses (75 mg administered morning and evening), for the shortest possible duration and under close monitoring (See WARNINGS and PRECAUTIONS- Cardiovascular).</li><li>In elderly patients, and patients with renal insufficiency, hepatic impairment or with a cardiovascular risk, the maximum daily dose should not exceed 100 mg of diclofenac (see Dosing Considerations).</li><li>APO-DICLO SR tablets should be swallowed whole with liquid, preferably at mealtime.</li></ul><p>&nbsp;</p><p><strong>Missed Dose</strong></p><p>Patients who miss one or more doses of APO-DICLO (diclofenac sodium) 25 and 50 mg tablets or APO-DICLO SR 75 and 100 mg tablets should not increase the dose of APO-DICLO (diclofenac sodium) or APO-DICLO SR to compensate for the missed dose or doses, but should continue with their therapy as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diclofenac is contraindicated in following conditions:
a.	Ischemic heart disease
b.	Peripheral arterial disease
c.	Cerebrovascular disease
d.	Congestive heart failure (New York Heart Association [NYHA] classification II- IV)

• the peri-operative setting of coronary artery bypass graft surgery (CABG). Although APO- DICLO and APO-DICLO SR have NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications.
• the third trimester	of pregnancy, because of risk of premature	closure of the ductus arteriosus and prolonged parturition
• women who are breastfeeding, because of the potential for serious adverse reactions in nursing infants
• severe uncontrolled heart failure
• known	hypersensitivity to APO-DICLO	or APO-DICLO SR	or to any of the components/excipients
• history of asthma, urticaria, or allergic-type reactions after taking ASA or other NSAIDs (i.e. complete	or	partial	syndrome	of	ASA-intolerance-rhinosinusitis, urticaria/ angioedema, nasal polyps, asthma). Fatal anaphylactoid reactions have occurred in such individuals. Individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction. The potential for cross- reactivity between different NSAIDs must be kept in mind (see WARNINGS AND PRECAUTIONS _Hypersensitivity Reactions - Anaphylactoid Reactions).
• active gastric I duodenal I peptic ulcer, active Gl bleeding or perforation, regional ulcer, gastritis or ulcerative colitis
• cerebrovascular bleeding or other bleeding disorders
• inflammatory bowel disease
• severe liver impairment or active liver disease
• severe renal impairment (creatinine clearance <30 ml/min or 0.5 ml/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored) (see WARNINGS AND PRECAUTIONS - Renal)
• known hyperkalemia (see WARNINGS AND PRECAUTIONS - Renal - Fluid and Electrolyte Balance)
• children and adolescents less than 16 years of age

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, and smoking) .</p><p>As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically .</p></td></tr></tbody></table><p><strong>General</strong></p><p>Frail or debilitated patients may tolerate side effects less well and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible duration. As with other NSAIDs, caution should be used in the treatment of elderly patients who are more likely to be suffering from impaired renal, hepatic or cardiac function. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p><p>Diclofenac sodium (enteric coated tablets and slow release tablets) are NOT recommended for use with other NSAIDs, with the exception of low-dose ASA for cardiovascular prophylaxis, because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions. (See DRUG INTERACTIONS -Drug/Drug Interactions- <em>Acetylsalicylic acid (ASA) or other NSAIDs)</em></p><p>Diclofenac sodium should not be used concomitantly with diclofenac potassium (such as Apo-Diclo Rapide) since both exist in plasma as the same active organic ion.</p><p>&nbsp;</p><p><strong>Carcinogenesis and Mutagenesis</strong></p><p><em>Mutagenicity Studies</em></p><p>Mutagenicity studies were carried out <em>in vitro </em>using bacteria with, and without microsomal activation, and in mammalian cells. Studies <em>in vivo </em>were also performed. Diclofenac sodium was not mutagenic in any of these test systems.</p><p>&nbsp;</p><p><em>Carcinogenicity Studies</em></p><p>Long-term carcinogenicity studies in rats given diclofenac sodium up to 2 mg/kg/day have revealed no significant increases in tumour incidence. There was a positive dose-related trend with respect to adrenal medullary hyperplasia, mammary fibroadenomas and subcutaneous tissue fibromas in females, as well as of C-cell adenomas of the thyroid in males. The differences in the incidence between the various groups, including control, were small and were considered to reflect the variation in the spontaneous occurrence of these incidental lesions, common in old laboratory rats.</p><p>&nbsp;</p><p>In a 2-year mouse study, only controls and animals at the two lower daily doses of 0.1 and 0.3 mg/kg showed survival sufficient for assessment of carcinogenic potential. The two higher daily doses of 1 and 2 mg/kg resulted in a shortening of lifespan, particularly in males, as a consequence of ulceration and/or perforation of the small intestine and therefore prevented evaluation. The known susceptibility of rodents to non-steroidal anti-inflammatory drugs, resulting in high mortality at dose levels close to the therapeutic dose, is considered to be a rodent-specific effect. Diclofenac sodium was not carcinogenic to mice under the conditions of this study.</p><p>&nbsp;</p><p><strong>Cardiovascular</strong></p><p>Diclofenac sodium (enteric coated tablets and slow release tablets) are non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. Large population-based observational studies, meta-analyses and systematic reviews suggest an increased risk of myocardial infarction and stroke also in association with the use of diclofenac. The risk may increase with the dose and duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.</p><p>&nbsp;</p><p>Caution should be exercised in prescribing diclofenac sodium (enteric coated tablets and slow release tablets) to patients with risk factors for cardiovascular disease, cerebrovascular disease or renal disease, such as any of the following (NOT an exhaustive list):</p><ul><li>Hypertension</li><li>Dyslipidemia <em>I </em>Hyperlipidemia</li><li>Diabetes Mellitus</li><li>Congestive Heart Failure (NYHA I)</li><li>Coronary Artery Disease (Atherosclerosis)</li><li>Peripheral Arterial Disease</li><li>Smoking</li><li>Creatinine Clearance&lt; 60 mL/min or 1 mUsec</li></ul><p>Use of NSAIDs, such as diclofenac sodium (enteric coated tablets and slow release tablets), can lead to new hypertension or can worsen pre-existing hypertension, either of which may increase the risk of cardiovascular events as described above. Thus blood pressure should be monitored regularly. Consideration should be given to discontinuing diclofenac sodium (enteric coated tablets and slow release tablets) should hypertension either develop or worsen with its use.</p><p>&nbsp;</p><p>Use of NSAIDs, such as diclofenac sodium (enteric coated tablets and slow release tablets), can induce fluid retention and edema, and may exacerbate congestive heart failure, through a renally- mediated mechanism. (See WARNINGS AND PRECAUTIONS - Renal <em>-Fluid and Electrolyte Balance).</em></p><p><em>&nbsp;</em></p><p>For patients with a high risk of developing an adverse CV event, other management strategies that do NOT include the use of NSAIDs should be considered first. To minimize the potential risk for an adverse CV event, the lowest effective dose should be used for the shortest possible duration.</p><p>&nbsp;</p><p><strong>Endocrine and Metabolism</strong></p><p><em>Corticosteroids: </em>Diclofenac sodium (enteric coated tablets and slow release tablets) are NOT a substitute for corticosteroids. They do NOT treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. (see DRUG INTERACTIONS - Drug-Drug Interactions <em>-</em><em> Glucocorticoids)</em></p><p><em>&nbsp;</em></p><p><strong>Gastrointestinal (GI)</strong></p><p>Serious Gl toxicity (sometimes fatal), such as peptic/duodenal ulceration, inflammation, perforation, obstruction and gastrointestinal bleeding, can occur at any time, with or without warning symptoms, in patients treated with NSAIDs, such as diclofenac sodium (enteric coated or slow release tablets). Minor upper Gl problems, such as dyspepsia, commonly occur at any time. Health care providers should remain alert for ulceration and bleeding in patients treated with diclofenac sodium (enteric coated tablets or slow release tablets), even in the absence of previous Gl tract symptoms. Most spontaneous reports of fatal Gl events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse Gl event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. (see WARNINGS AND PRECAUTIONS _Special Populations <em>_Geriatrics)</em></p><p><em>&nbsp;</em></p><p>Patients should be informed about the signs and/or symptoms of serious Gl toxicity and instructed to discontinue using diclofenac sodium (enteric coated tablets or slow release tablets) and seek emergency medical attention if they experience any such symptoms. The utility of periodic laboratory monitoring has NOT been demonstrated, nor has it been adequately assessed. Most patients who develop a serious upper Gl adverse event on NSAID therapy have no symptoms. Upper Gl ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue, thus increasing the likelihood of developing a serious Gl event at some time during the course of therapy. Even a short-term therapy has its risks.</p><p>&nbsp;</p><p>Caution should be taken if prescribing diclofenac sodium (enteric coated tablets or slow release tablets) to patients with a prior history of peptic <em>I </em>duodenal ulcer disease or gastrointestinal bleeding as these individuals have a greater than 10-fold higher risk for developing a Gl bleed when taking a NSAID than patients with neither of these risk factors. Other risk factors for Gl ulceration and bleeding include the following: <em>He/icobacter pylori </em>infection, increased age, prolonged use of NSAID therapy, excess alcohol intake, smoking, poor general health status or concomitant therapy with any of the following:</p><p>&nbsp;</p><ul><li>Anti-coagulants (e.g. warfarin)</li><li>Anti-platelet agents (e.g. ASA, clopidogrel)</li><li>Oral corticosteroids (e.g. prednisone)</li><li>Selective Serotonin Reuptake Inhibitors (SSRis) (e.g. citalopram, fluotexine, paroxetine, sertraline)</li></ul><p>There is no definitive evidence that the concomitant administration of histamine H2-receptor antagonists and/or antacids will either prevent or reduce the occurrence of gastrointestinal adverse events associated with the use of diclofenac sodium slow release tablet or the enteric- coated formulation of diclofenac sodium. Concurrent administration of histamine H2-receptor antagonists and/or antacids with the enteric-coated version of diclofenac sodium might results in altered absorption.</p><p>&nbsp;</p><p><strong>Genitourinary</strong></p><p>Some NSAIDs are associated with persistent urinary symptoms (bladder pain, dysuria, urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with an NSAID. Should urinary symptoms occur, in the absence of an alternate explanation, treatment with diclofenac sodium (enteric coated tablets or slow release tablets) should be stopped to ascertain if symptoms disappear. This should be done before urological investigations or treatments are carried out.</p><p>&nbsp;</p><p><strong>Hematologic</strong></p><p>NSAIDs inhibiting prostaglandin biosynthesis interfere with platelet function to varying degrees; patients who may be adversely affected by such an action, such as those on anti-coagulants or suffering from hemophilia or platelet disorders should be carefully observed when diclofenac sodium (enteric coated tablets or slow release tablets) is administered.</p><p>&nbsp;</p><p><em>Anti-coagulants: </em>Numerous studies have shown that the concomitant use of NSAIDs and anti- coagulants increases the risk of bleeding. Concurrent therapy of diclofenac sodium (enteric coated tablets or slow release tablets) with warfarin requires close monitoring of the international normalized ratio (INR).</p><p>Even with therapeutic INR monitoring, increased bleeding may occur.</p><p>&nbsp;</p><p><em>Anti-platelet Effects: </em>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike Acetylsalicylic acid (ASA), their effect on platelet function is quantitatively less, or of shorter duration, and is reversible.</p><p>Diclofenac sodium (enteric coated tablets and slow release tablets) and other NSAIDs have no proven efficacy as anti-platelet agents and should NOT be used as a substitute for ASA or other anti- platelet agents for prophylaxis of cardiovascular thromboembolic diseases. Anti-platelet therapies (e.g. ASA) should NOT be discontinued. There is some evidence that use of NSAIDs with ASA can markedly attenuate the cardioprotective effects of ASA. (see DRUG INTERACTIONS -Drug-Drug Interactions <em>-Acetylsalicylic</em><em> </em><em>Acid</em><em> </em><em>(ASA)</em><em> </em><em>or other NSAIDs)</em></p><p><em>&nbsp;</em></p><p>Concomitant administration of diclofenac sodium (enteric coated tablets or slow release tablets) with low dose ASA increases the risk of Gl ulceration and associated complications.</p><p>&nbsp;</p><p><em>Blood dyscrasias: </em>Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anemia and agranulocytosis) associated with the use of NSAIDs are rare, but could occur with severe consequences.</p><p>&nbsp;</p><p>Anemia is sometimes seen in patients receiving NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets). This may be due to fluid retention, Gl blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets), should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss.</p><p>&nbsp;</p><p><strong>Hepatic/Biliary/Pancreatic</strong></p><p>As with other NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets), borderline elevations of one or more liver enzyme tests (AST, ALT, alkaline phosphatase) may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy.</p><p>&nbsp;</p><p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction, while on therapy with diclofenac sodium (enteric coated tablets or slow release tablets). Severe hepatic reactions including jaundice and cases of fatal hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported with diclofenac sodium (enteric coated tablets and slow release tablets).</p><p>&nbsp;</p><p>Although such reactions are rare, if abnormal liver function tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop (e.g. jaundice), or if systemic manifestations occur (e.g. eosinophilia, associated with rash etc.), this drug should be discontinued.</p><p>If there is a need to prescribe this drug in the presence of impaired liver function, it must be done under strict observation.</p><p>&nbsp;</p><p>Caution is advised when using diclofenac sodium (enteric coated tablets or slow release tablets) in patients with hepatic porphyria, since diclofenac sodium (enteric coated tablets or slow release tablets) may trigger an attack.</p><p>&nbsp;</p><p><strong>Hypersensitivity reactions</strong></p><p><em>Anaphylactoid reactions: </em>As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to diclofenac sodium (enteric coated tablets or slow release tablets). In post-marketing experience, rare cases of anaphylactic/ anaphylactoid reactions and angioedema have been reported in patients receiving diclofenac sodium (enteric coated tablets or slow release tablets). Diclofenac sodium (enteric coated tablets or slow release tablets) should NOT be given to patients with the ASA-triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking ASA or other NSAIDs (see CONTRAINDICATION).</p><p>&nbsp;</p><p><strong>ASA-intolerance</strong></p><p>Diclofenac sodium (enteric coated tablets or slow release tablets) should NOT be given to patients with complete or partial syndrome of ASA-intolerance (rhinosinusitis, urticaria/angioedema, nasal polyps, asthma) in whom asthma, anaphylaxis, urticaria/angioedema, rhinitis or other allergic manifestations are precipitated by ASA or other NSAIDs. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction. (See CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong><em>Cross-sensitivity: </em></strong>Patients sensitive to any one of the NSAIDs may be sensitive to any of the other NSAIDs as well.</p><p>&nbsp;</p><p><strong><em>Serious</em></strong><strong><em> </em></strong><strong><em>Skin</em></strong><strong><em> </em></strong><strong><em>Reactions:</em></strong></p><p>(See WARNINGS AND PRECAUTIONS - Skin)</p><p>&nbsp;</p><p><strong>Immune</strong></p><p>(See WARNINGS AND PRECAUTIONS. Infection - <em>Aseptic Meningitis)</em></p><p><em>&nbsp;</em></p><p><strong>Infection</strong></p><p>Diclofenac sodium (enteric coated tablets and slow release tablets), in common with other NSAIDs, may mask signs and symptoms of an underlying infectious disease.</p><p>&nbsp;</p><p><em>Aseptic Meningitis: </em>Rarely, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissue diseases, etc.) seem to be pre-disposed. Therefore, in such patients, the health care provider must be vigilant to the development of this complication.</p><p>&nbsp;</p><p><strong>Neurologic</strong></p><p>Some patients may experience drowsiness, dizziness, blurred v1s1on, vertigo, insomnia, depression, tinnitus or hearing loss with the use of NSAIDs, such as diclofenac sodium (enteric coated tablets and slow release tablets). If patients experience such adverse reaction(s) they should exercise caution in carrying out activities that require alertness.</p><p>&nbsp;</p><p><strong>Ophthalmologic</strong></p><p>Blurred and/or diminished vision has been reported with the use of NSAIDs. If such symptoms develop, Diclofenac sodium (enteric coated tablets or slow release tablets) should be discontinued and an ophthalmologic examination performed. Ophthalmologic examination should be carried out at periodic intervals in any patient receiving diclofenac sodium (enteric</p><p>&nbsp;</p><p>coated tablets or slow release tablets) for an extended period of time.</p><p>Sun exposure in patients using diclofenac sodium (enteric coated tablets or slow release tablets) might cause photosensitivity and vision changes. Patients should be advised to contact their physician for assessment and advice if this occurs.</p><p>&nbsp;</p><p><strong>Peri-Operative Considerations</strong></p><p>(See CONTRAINDICATIONS- Coronary Artery Bypass Graft Surgery)</p><p>&nbsp;</p><p><strong>Psychiatric</strong></p><p>(See WARNINGS AND PRECAUTIONS - Neurologic)</p><p>&nbsp;</p><p><strong>Renal</strong></p><p>Long term administration of NSAIDs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis, hematuria, low grade proteinuria and occasionally nephrotic syndrome. During long-term therapy, kidney function should be monitored periodically. (See PHARMACOLOGICAL PROPERTIES)</p><p>&nbsp;</p><p>Renal insufficiency due to NSAID use is seen in patients with pre-renal conditions leading to reduction in renal blood flow or blood volume. Under these circumstances, renal prostaglandins help maintain renal perfusion and glomerular filtration rate (GFR). In these patients, administration of a NSAID may cause a reduction in prostaglandin synthesis leading to impaired renal function. Patients at greatest risk of this reaction are those with pre-existing renal insufficiency (GFR&lt; 60 ml/min or 1 ml/s), dehydrated patients, patients on salt restricted diets, those with congestive heart failure, cirrhosis, liver dysfunction, taking angiotensin-converting enzyme inhibitors, angiotensin-11 receptor blockers, cyclosporin, diuretics, and those who are elderly. Serious or life-threatening renal failure has been reported in patients with normal or impaired renal function after short term therapy with NSAIDs. Even patients at risk who demonstrate the ability to tolerate a NSAID under stable conditions may decompensate during periods of added stress (e.g. dehydration due to gastroenteritis). Discontinuation of NSAIDs is usually followed by recovery to the pre-treatment state.</p><p>&nbsp;</p><p>Caution should be used when initiating treatment with NSAIDs, such as diclofenac sodium (enteric coated tablets or slow release tablets), in patients with considerable dehydration. Such patients should be rehydrated prior to initiation of therapy. Caution is also recommended in patients with pre-existing kidney disease. (See WARNING AND PRECAUTIONS-Monitoring and Laboratory Tests <em>-Renal)</em></p><p><em>&nbsp;</em></p><p><strong><em>Advanced</em></strong><strong><em> </em></strong><strong><em>Renal</em></strong><strong><em> </em></strong><strong><em>Disease:</em></strong><strong><em> </em></strong></p><p>(See CONTRAINDICATIONS)</p><p><em>Fluid and Electrolyte Balance: </em>Use of NSAIDs, such as diclofenac sodium (enteric coated tablets or slow release tablets), can promote sodium retention in a dose-dependant manner, which can lead to fluid retention and edema, and consequences of increased blood pressure and exacerbation of congestive heart failure. Thus, caution should be exercised in prescribing diclofenac sodium (enteric coated tablets or slow release tablets) in patients with a history of congestive heart failure, compromised cardiac function, hypertension, increased age or other conditions predisposing to fluid retention. (See WARNINGS AND PRECAUTIONS - Cardiovascular).</p><p>&nbsp;</p><p>Use of NSAIDs, such as diclofenac sodium (enteric coated tablets or slow release tablets), can increase the risk of hyperkalemia, especially in patients with diabetes mellitus, renal failure, increased age, or those receiving concomitant therapy with adrenergic blockers, angiotensin- converting enzyme inhibitors, angiotensin-11 receptor antagonists, cyclosporin, or some diuretics. Electrolytes should be monitored periodically. (See CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong>Respiratory</strong></p><p>ASA-induced asthma is an uncommon but very important indication of ASA and NSAIDs sensitivity. It occurs more frequently in patients with asthma who have nasal polyps.</p><p>&nbsp;</p><p><em>Pre-existing</em><em> </em><em>asthma: </em>In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics <em>I </em>analgesics-asthma), Quincke&#39;s oedema or urticaria are more frequent than in other patients. Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria.</p><p>&nbsp;</p><p><strong>Skin</strong></p><p>In rare cases, serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis and erythema multiforme have been associated with the use of some NSAIDs. Because the rate of these reactions is low, they have usually been noted during post-marketing surveillance in patients taking other medications also associated with the potential development of these serious skin reactions. Thus, causality is NOT clear. These reactions are potentially life threatening but may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients should be advised that if they experience a skin rash they should discontinue their NSAID and contact their physician for assessment and advice, including which additional therapies to discontinue.</p><p>Use of diclofenac sodium (enteric coated tablets or slow release tablets) may cause photosensitivity upon exposure to sunlight or UV light causing symptoms such as sunburn, skin rash, skin blisters, pruritus, erythema and discolouration.</p><p>&nbsp;</p><p><strong>Special Populations</strong></p><p><em>Pregnant Women: </em>Diclofenac sodium (enteric coated tablets or slow release tablets) are CONTRAINDICATED for use during the third trimester of pregnancy because of risk of premature closure of the ductus arteriosus and the potential to prolong parturition (see TOXICOLOGY).</p><p>Caution should be exercised in prescribing diclofenac sodium (enteric coated tablets and slow release tablets) during the first and second trimesters of pregnancy (see TOXICOLOGY).</p><p>&nbsp;</p><p>Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or the embryofoetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.</p><p>&nbsp;</p><p>In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p>Diclofenac sodium readily crosses the placental barrier.</p><p><strong><em>Nursing</em></strong><strong><em> </em></strong><strong><em>Women</em></strong><em>:</em><em> </em>(see CONTRAINDICATIONS)</p><p><strong><em>Pediatrics:</em></strong><strong><em> </em></strong>(see CONTRAINDICATIONS)</p><p><strong><em>Geriatrics</em></strong><em>: </em>Patients older than <em>65 </em>years (referred to in this document as older or elderly) and frail or debilitated patients are more susceptible to a variety of adverse reactions from NSAIDs; the incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. Most reports of fatal Gl events are in this population. Older patients are also at risk of lower esophageal injury including ulceration and bleeding.</p><p>&nbsp;</p><p>For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision.</p><p>&nbsp;</p><p><strong>Monitoring and Laboratory Tests</strong></p><p><em>Cardiovascular (Hypertension): </em>Blood pressure should be monitored regularly during therapy with diclofenac sodium (enteric coated tablets or slow release tablets).</p><p>&nbsp;</p><p><em>Hematologic: </em>Patients on long-term treatment with diclofenac sodium (enteric coated tablets or slow release tablets) should have their hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), and platelets checked if they exhibit any signs or symptoms of anemia or blood loss or blood dyscrasia.</p><p>&nbsp;</p><p><em>Hepatic: </em>Hepatic function (e.g. serum transaminases, bilirubine) should be monitored regularly during therapy with diclofenac sodium (enteric coated tablets or slow release tablets).</p><p>&nbsp;</p><p><em>Ophthalmologic: </em>Patients on long-term treatment with diclofenac sodium (enteric coated tablets or slow release tablets) should have an ophthalmologic examination performed periodically, and if they experience blurred and/or diminished vision.</p><p>&nbsp;</p><p><em>Renal: </em>Patients with pre-existing renal insufficiency (GFR &lt; 60 ml/min or 1 ml/s), dehydrated patients, patients on salt restricted diets, those with congestive heart failure, cirrhosis, liver dysfunction, taking angiotensin-converting enzyme inhibitors, angiotensin-11 receptor blockers, cyclosporin, diuretics, and the elderly should have their renal function monitored (e.g. urine output, serum creatinine, creatinine clearance and serum urea) during therapy with diclofenac sodium (enteric coated tablets or slow release tablets).</p><p>&nbsp;</p><p>Electrolytes, including serum potassium, should be monitored periodically, especially in patients with diabetes mellitus, renal failure, increased age, or those receiving concomitant therapy with adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-11 receptor antagonists, cyclosporin, or some diuretics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drug-Drug Interactions</strong></p><p>Table 3: Established Potential Drug-Drug Interactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Diclofenac sodium (enteric coated tablets or slow release tablets)</strong></p></td><td style="vertical-align:top"><p><strong>Clinical comment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acetaminophen</p></td><td style="vertical-align:top"><p>There may be an increased risk of adverse renal effects when administered concomitantly with NSAIDs.</p></td></tr><tr><td style="vertical-align:top"><p>Acetylsalicylic acid (ASA) or other NSAIDs</p></td><td style="vertical-align:top"><p>The use of diclofenac sodium (enteric coated tablets or slow release tablets) in addition to any other NSAID, including over the counter ones (such as ASA and ibuprofen) for analgesic and/or anti- inflammatory effects is NOT recommended because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions.</p><p>&nbsp;</p><p>The exception is the use of low dose ASA for cardiovascular protection when another NSAID is being used for its analgesic/anti- inflammatory effect, keeping in mind that combination NSAID therapy is associated with additive adverse reactions.</p><p>&nbsp;</p><p>Some NSAIDs (e.g. ibuprofen) may interfere with the anti-platelet effects of low dose ASA, possible by competing with ASA for access to the active site of cyclooxygenase-1.</p><p>&nbsp;</p><p>Diclofenac sodium should not be used concomitantly with diclofenac potassium (such as Apo-Diclo Rapide) since both exist in plasma as the same active organic ion.</p><p>&nbsp;</p><p>Concomitant administration of diclofenac and other systemic NSAIDs or corticosteroids may increase the frequency of gastrointestinal undesirable effects.</p></td></tr><tr><td style="vertical-align:top"><p>Alcohol</p></td><td style="vertical-align:top"><p>There may be an increased risk of gastrointestinal side effects, including ulceration or hemorrhage, when administered concomitantly with NSAIDs.</p></td></tr><tr><td style="vertical-align:top"><p>Antacids</p></td><td style="vertical-align:top"><p>Concomitant administration of antacids with NSAIDs may affect the rate, but generally not the extent of the absorption of the NSAID</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p></td><td style="vertical-align:top"><p>(See WARNINGS AND PRECAUTIONS- Hematologic- <em>Anti</em><em> </em><em>coagulants)</em></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:127px"><p>Anti-hypertensives</p></td><td style="vertical-align:top; width:671px"><p>NSAIDs may diminish the anti-hypertensive effect of Angiotensin</p><p>Converting Enzyme (ACE) inhibitors.</p><p>&nbsp;</p><p>Combinations of ACE inhibitors, angiotensin-11 antagonists, or diuretics with NSAIDs might have an increased risk for acute renal failure and hyperkalemia. Blood pressure and renal function (including electrolytes) should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.(see WARNINGS AND PRECAUTIONS -Renal)</p><p>&nbsp;</p><p>Therefore the combination should be administered with caution and patients, especially the elderly (see WARNINGS AND PRECAUTIONS -Monitoring and Laboratorl Tests)</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Anti-platelet agents (including ASA)</p></td><td style="vertical-align:top; width:671px"><p>There is an increased risk of bleeding, via inhibition of platelet</p><p>function, when anti-platelet agents are combined with NSAIDs, such as diclofenac sodium (enteric coated tablets and slow release tablets) (see WARNINGS AND PRECAUTIONS _Hematologic _ <em>Anti-platelet Effects).</em></p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Cyclosporin or Tacrolimus</p></td><td style="vertical-align:top; width:671px"><p>Nephrotoxicity of cyclosporin and tacrolimus may be increased because of the effect of NSAIDs on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving cyclosporin or tacrolimus.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Digoxin</p></td><td style="vertical-align:top; width:671px"><p>Diclofenac may increase the plasma concentration of digoxin. Dosage adjustment may be required. Monitoring of serum digoxin level is recommended</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Diuretics</p></td><td style="vertical-align:top; width:671px"><p>Clinical studies as well as post-marketing observations have shown that NSAIDs can reduce the effect of diuretics. (see WARNINGS AND PRECAUTIONS -Renal).</p><p>&nbsp;</p><p>Class <em>Statement</em></p><p>Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium, thus making it necessary to monitor levels. (see WARNINGS AND PRECAUTIONS Monitoring and Laboratorl Tests <em>_Renal)</em></p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Glucocorticoids</p></td><td style="vertical-align:top; width:671px"><p>Some studies have shown that concomitant use of NSAIDS and oral glucocorticoids increases the risk of Gl adverse events such as ulceration and bleeding. This is especially the case in older (&gt;65 years of age) individuals.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Lithium</p></td><td style="vertical-align:top; width:671px"><p>Monitoring of plasma lithium concentrations is advised when stopping or starting a NSAID, as increased lithium concentrations can occur in patients taking lithium. Dosage adjustment of lithium may be required.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Methotrexate</p></td><td style="vertical-align:top; width:671px"><p>Caution should be exercised when NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets), are administered less than 24 hours before or after treatment with methotrexate. Elevated blood concentrations of methotrexate may occur, increasing toxicity.</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:127px"><p>Oral Hypoglycemics</p></td><td style="vertical-align:top; width:670px"><p>Pharmacodynamic studies have shown no potentiation of effect with concurrent administration with diclofenac; however, there are isolated reports of both hypoglycemic and hyperglycemic effects in the presence of diclofenac, which necessitated changes in the dosage of hypoglycemic agents. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Probenecid</p></td><td style="vertical-align:top; width:670px"><p>May decrease the excretion and increase serum concentrations of NSAIDs possibly enhancing effectiveness and/or increasing potential for toxicity. Concurrent therapy of NSAIDs with probenecid requires close monitoring to be certain that no change in dosage is necessary.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Quinolone antibacterials</p></td><td style="vertical-align:top; width:670px"><p>There have been isolated reports of convulsions which may have been due to concomitant use of quinolones and NSAIDs.</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Selective serotonin reuptake inhibitors (SSRis)</p></td><td style="vertical-align:top; width:670px"><p>Concomitant administration of NSAIOS, including diclofenac sodium</p><p>(enteric coated tablets and slow release tablets), and SSRis may increase the risk of gastrointestinal ulceration and bleeding. (see WARNINGS AND PRECAUTIONS- Gastrointestinal (GI))</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Drug-Food Interactions</strong></p><p>Interactions with food have not been established.</p><p>&nbsp;</p><p><strong>Drug-Herb Interactions</strong></p><p>Interactions with herbal products have not been established. Drug Laboratory Tests Interactions:</p><p>Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII. Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers. The mean changes were observed to be less than 1 second in both instances, and are unlikely to be clinically important.</p><p>Persistently abnormal or worsening renal, hepatic or hematological test values should be followed up carefully since they may be related to therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of diclofenac sodium (enteric coated tablets or slow release tablets), as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of diclofenac sodium (enteric coated tablets or slow release tablets) should be considered. (see <strong>TOXICOLOGY</strong>)<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients experiencing visual disturbances, dizziness, vertigo, somnolence or other central nervous system disturbances while taking diclofenac sodium (enteric coated tablets or slow release tablets) should refrain from driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><strong>&nbsp;Adverse Drug Reaction Overview</strong></em></p><p>Although not all adverse drug reactions have been reported with diclofenac sodium (enteric coated tablets or slow release tablets), the types of adverse drug reactions are expected to be similar to those of diclofenac potassium since both formulations exist in the plasma as the same active organic anion.</p><p>&nbsp;</p><p>Gastrointestinal, dermatological. CNS and hepatic adverse reactions are the most commonly seen with diclofenac. The most severe gastrointestinal adverse reactions observed were ulceration and bleeding, while the most severe dermatological albeit rare reactions observed with diclofenac were erythema multiforme (Stevens-Johnson Syndrome and Lyell Syndrome). Fatalities have occurred on occasion, particularly in the elderly.</p><p>&nbsp;</p><p>This section summarizes adverse drug reaction data pooled from clinical trials, published investigations and post-marketing experience with diclofenac potassium and diclofenac sodium.</p><p>&nbsp;</p><p><strong>Frequency estimate:</strong></p><p>Very common: &ge;10%</p><p>Common: &ge; 1% and &lt;10%</p><p>Uncommon: &ge; 0.01% and&lt; 1%</p><p>Very rare &lt;0.01%, including isolated reports.</p><p>&nbsp;</p><p>Table 1: Most Common Adverse Drug Reactions (1%)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Gastrointestinal</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Very</p><p>common</p></td><td style="vertical-align:top"><p>nausea, vomiting, diarrhea, dyspepsia,</p><p>abdominal pain, flatulence, anorexia</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous</em><em> </em><em>System</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dizziness, headache, vertigo</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatic</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>elevations (&ge; 3 times the upper normal limit) of</p><p>serum aminotransferase enzymes (SGOT or AST, SGPT or ALT).</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin</em><em> </em><em>and</em><em> </em><em>subcutaneous</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 2: Less Common Adverse Drug Reactions (&lt;1%)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" rowspan="2"><p><em>Gastrointestinal</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>gastritis, gastrointestinal hemorrhage, hemorrhagic diarrhea, melena, hematemesis gastric and intestinal ulcerations (with or without bleeding or perforation)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>lower gut disorders (including hemorrhagic</p><p>colitis and exacerbation of ulcerative colitis or Crohn&#39;s disease), diaphragm-like intestinal strictures, hyperacidity, stomatitis,</p><p>glossitis, coated tongue, esophageal lesions,</p><p>constipation, pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous</em><em> </em><em>System</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>drowsiness, malaise, impaired concentration,</p><p>tiredness</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Nervous System</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>sensory disturbances including paresthesia, memory disturbance, convulsions, anxiety, tremor, aseptic meningitis, cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage)</p></td></tr><tr><td style="vertical-align:top"><p><em>Special</em><em> </em><em>senses</em></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>vision disturbances (blurred vision, diplopia), impaired hearing, tinnitus, taste alteration disorders</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Cardiac</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>palpitation, angina, arrhythmias</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>exacerbation of cardiac failure, hypertension, myocardial infarction</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Skin</em><em> </em><em>and</em><em> </em><em>subcutaneous</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>bullous eruption, erythema, eczema, erythema</p><p>multiforme, Stevens-Johnson Syndrome, Lyell Syndrome (toxic epidermal necrolysis), erythroderma (exfoliative dermatitis), loss of hair, photosensitivity reactions, purpura, allergic purpura</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Renal</em><em> </em><em>and</em><em> </em><em>urinary</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>edema (facial, general, peripheral)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>acute renal failure, nephrotic syndrome, urinary abnormalities (e.g., hematuria and proteinuria), interstitial nephritis, renal papillary necrosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Hematologic</em></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>thrombocytopenia, leukopenia, agranulocytosis, hemolytic anemia, aplastic anemia, anemia secondary to gastrointestinal bleeding</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Hepatic</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>liver function disorders including hepatitis,</p><p>jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>fulminant hepatitis</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Immune</em><em> </em><em>system</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypersensitivity anaphylactic <em>I </em>anaphylactoid systemic reactions (including hypotension and shock)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>angioneurotic edema, (including face edema)</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>disorientation, depression, insomnia, nightmare, irritability, psychotic disorder</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><em>Respiratory</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>asthma</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>pneumonitis</p></td></tr></tbody></table><p><strong>Post-Market Adverse Drug Reactions</strong></p><p><em>Hepatic: </em>hepatic necrosis, hepatic failure</p><p>&nbsp;</p><p><strong>To</strong><strong> report any side effect(s)</strong></p><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia:</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p><br /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:360.75pt;
 height:35.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:570px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="width:567px"><p>For management of a suspected drug overdose, contact your regional Poison Control Center Immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Symptoms</strong></p><p>There is no typical clinical picture resulting from diclofenac overdosage. Overdosage can cause symptoms such as vomiting, gastrointestinal haemorrhage, diarrhoea, dizziness, tinnitus or convulsions. In the event of significant poisoning, acute renal failure and liver damage are possible.</p><p>&nbsp;</p><p><strong>Therapeutic measures</strong></p><p>Management of acute poisoning with NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets), essentially consists of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression. Special measures such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs, including diclofenac sodium (enteric coated tablets and slow release tablets), due to the high protein binding and extensive metabolism. Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric decontamination (e.g. vomiting, gastric lavage) after ingestion of a potentially life threatening overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of diclofenac sodium (enteric coated tablets or slow release tablets) are largely mediated by inhibition of cyclooxygenases (COXs, COX-1, COX-2). These enzymes are found throughout the body and produce prostaglandins, which are important mediators of pain, fever, and adaptive and protective reactions in many organs and (inflamed) tissues.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong> In humans, orally-administered diclofenac sodium is rapidly and almost completely absorbed and distributed to blood, liver, and kidneys. The plasma concentrations show a linear relationship to the amount of drug administered. No accumulation occurs provided the recommended dosage intervals are observed.</p><p>&nbsp;</p><p>Enteric coating may delay the onset of absorption from 25 and 50 mg tablets. Absorption occurs more rapidly when the drug is administered on an empty stomach &lt;Tmax 2.5 hours), than with meals (Tmax 6 hours). The bioavailability remains the same under both conditions. The mean peak plasma concentration of 1.5 ug/mL <em>(5 </em>umol/L) is attained, on average, 2 hours after ingestion of one 50 mg enteric-coated tablet.</p><p>&nbsp;</p><p>Following&nbsp;&nbsp;&nbsp; administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of slow-release&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (SR) diclofenac&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium,&nbsp;&nbsp;&nbsp; C max,&nbsp;&nbsp; is reached&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at approximately 4 hours or later. Significant drug plasma concentrations persist when levels would have dropped almost to baseline values following enteric-coated tablet administration.</p><p>Mean plasma concentrations of 13 ng/ml(40 nmol/L) were produced 24 hours after diclofenac sodium slow-release (SR) 100 mg tablets, or 16 hours after diclofenac sodium slow-release (SR) 75 mg tablets (single dose). Trough levels are approximately 22-25 ng/ml(70-80 nmol/L) during treatment with diclofenac sodium slow-release (SR) 100 mg tablets once daily or diclofenac sodium slow-release (SR) 75 mg tablets twice daily. In pharmacokinetic studies no accumulation of diclofenac sodium was found following repeated once daily administration of diclofenac sodium slow-release (SR) 100 mg tablets or repeated twice daily administration of diclofenac sodium slow-release (SR) 75 mg tablets.</p><p>&nbsp;</p><p><strong>Distribution: </strong>Diclofenac sodium is extensively bound (99%) to serum albumin. The apparent volume of distribution is 0.12 to 0.17 L/kg. Single-dose (P.O. or I.M) studies in rheumatoid patients with joint effusions have shown that diclofenac is distributed to the synovial fluid, where Tmax occurs 2 to 4 hours after plasma <strong>T</strong>max Synovial fluid concentrations exceed plasma levels within 4 to 6 hours of administration. This elevation above plasma concentrations can be maintained for up to 12 hours. The synovial fluid elimination half-life is at least 3 times greater than that for plasma.</p><p>&nbsp;</p><p><strong>Metabolism: </strong>Diclofenac undergoes single and multiple hydroxylation and methoxylation, producing 3&#39;-, 4&#39;-, 5-hydroxy, 4&#39;- 5-hydroxy and 3&#39;-hydroxy-4&#39;-methoxy derivatives of diclofenac. These phenolic metabolites are largely inactive, and (along with the parent compound) are mostly converted to glucuronide conjugates.</p><p>&nbsp;</p><p><strong>Excretion:</strong><strong> </strong>Plasma clearance of diclofenac is 263 &plusmn;56 ml/min. The mean terminal drug half-life in plasma is 1.8 hours after oral doses. In humans about 60% of the drug and its metabolites are eliminated in the urine and the balance through bile in the feces. More than 90% of an oral dose is accounted for in elimination products within 72 hours. About 1% of an oral dose is excreted unchanged in urine.</p><p>&nbsp;</p><p><strong>Special Populations and Conditions</strong></p><p>&nbsp;</p><p><strong><em>Renal Impairment: </em></strong>In patients suffering from renal impairment, no accumulation of the unchanged active substance can be inferred from the single-dose kinetics when applying the usual dosage schedule. At a creatinine clearance of &lt;10 ml/min, the calculated steady-state plasma levels of the hydroxy metabolites are about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile. Although no accumulation of pharmacologically active substance seem to occur, caution is advised while administering diclofenac sodium (enteric coated tablets or slow release tablets) to patients with impaired kidney function (i.e. GFR &lt; 60 ml/min or 1 ml/sec) (see <strong>WARNINGS AND PRECAUTIONS. Renal . </strong>Diclofenac sodium (enteric coated tablets and slow release tablets) are contraindicated in patients with severely impaired or deteriorating renal function (creatinine clearance &lt; 30 ml/min (0.5 ml/s) (see <strong>CONTRAINDICATIONS).</strong></p><p><strong>&nbsp;</strong></p><p><em><strong>Hepatic Impairment:</strong> </em>In a study of ten patients with impaired hepatic function (chronic hepatitis and non-decompensated cirrhosis) receiving a single oral dose of 100 mg diclofenac sodium, the kinetics and metabolism of diclofenac, were the same as in patients without liver disease.</p><p>&nbsp;</p><p><em>Pediatrics: </em>Diclofenac sodium (enteric coated tablets and slow release tablets) are contraindicated in children and adolescents less than 16 years of age. (see CONTRAINDICATIONS)</p><p>&nbsp;</p><p><em>Geriatrics: </em>The ability of elderly subjects to absorb, metabolize and excrete diclofenac sodium (enteric coated tablets or slow release tablets) does not appear to differ significantly from those of younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute Toxicity</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Species</p></td><td style="vertical-align:top"><p>Route</p></td><td style="vertical-align:top"><p>LD50&nbsp;(mg/kg)</p></td><td style="vertical-align:top"><p>95% Confidence Limits (mg/kg)</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Mouse</p></td><td style="vertical-align:top"><p>P.O.</p></td><td style="vertical-align:top"><p>389</p></td><td style="vertical-align:top"><p>197- &nbsp;595</p></td></tr><tr><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>133</p></td><td style="vertical-align:top"><p>126- 140</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Rat</p></td><td style="vertical-align:top"><p>P.O.</p></td><td style="vertical-align:top"><p>173</p></td><td style="vertical-align:top"><p>133-213</p></td></tr><tr><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>106</p></td><td style="vertical-align:top"><p>80-132</p></td></tr><tr><td style="vertical-align:top"><p>Guinea-pig</p></td><td style="vertical-align:top"><p>P.O.</p><p>I.V.</p></td><td style="vertical-align:top"><p>1110</p><p>127</p></td><td style="vertical-align:top"><p>950-1270</p><p>123- 132</p></td></tr><tr><td style="vertical-align:top"><p>Rabbit</p></td><td style="vertical-align:top"><p>P.O.</p></td><td style="vertical-align:top"><p>194</p></td><td style="vertical-align:top"><p>151-259</p></td></tr></tbody></table><p>The symptoms included bradycardia and convulsions.</p><p>The most frequent autopsy findings in animals that died were gastric irritation, perforation and their squeal.</p><p>&nbsp;</p><p><strong>Long-Term Toxicity Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Species</p></td><td style="vertical-align:top"><p>Period</p></td><td style="vertical-align:top" colspan="3"><p>Daily Dose mg/kg/day &nbsp;P.O.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>No signs &nbsp;of</p><p>intoxication</p></td><td style="vertical-align:top"><p>Reversible signs of</p><p>toxicity, mainly &nbsp;Gl Tract</p></td><td style="vertical-align:top"><p>Minimum lethal</p><p>dose</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>3 months</p><p>6 months</p><p>98 weeks</p></td><td style="vertical-align:top"><p>2</p><p>1</p><p>0.25</p></td><td style="vertical-align:top"><p>-</p><p>2</p><p>-</p></td><td style="vertical-align:top"><p>6</p><p>4</p><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>3 months</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Rhesus &nbsp;Monkey</p></td><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5-15</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>Baboon</p></td><td style="vertical-align:top"><p>12months</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>10</p></td></tr></tbody></table><p>&nbsp;</p><p>Diclofenac sodium was given orally to male and female rats in doses of&nbsp; 0.25, 1.0 and &nbsp;2.0 mg/kg/day from 59 weeks (high-dose groups) to 98 weeks (low- and intermediate-dose groups). High dose-related mortality rates resulted in termination of the high-dose&nbsp; administration after 59 weeks; the high mortality rate was caused by severe dose-dependent ulceration of the gastrointestinal tract, with perforated ulcers leading to peritonitis &nbsp;and &nbsp;sequelae. &nbsp;Body-weight gains and feed consumption of the treated groups were close to &nbsp;the &nbsp;controls. &nbsp;Hematologic patterns showing neutrophilic leucocytosis and anemia were seen in the high- and intermediate- dose groups, particularly females at weeks 52 and 98, respectively. Female animals tended to develop enlarged adrenals &nbsp;and &nbsp;eventually &nbsp;experienced &nbsp;depressed &nbsp;glucose &nbsp;and &nbsp;elevated alkaline phosphatase levels. Histology studies carried&nbsp; out on the tissues of the control, low- and intermediate-dose groups showed drug-related changes including &nbsp;mucosal &nbsp;ulceration &nbsp;of &nbsp;the small intestine, lymphangiectasis, lymphoid hypoplasia, and plasma&nbsp; cell hypoplasia of the mesenteric lymph nodes, foci of hepatocytic hyperplasia, adrenal cortical atrophy and prostatitis. No increase in tumour&nbsp; incidence was observed in the drug-treated groups as compared to the control group.</p><p>&nbsp;</p><p>Diclofenac sodium was administered orally in gelatin capsules once daily &nbsp;to baboons &nbsp;<em>(Papio spp.) </em>at dose levels of 0, 5, 15 (reduced to 10 on day 254) and 50 (reduced to 30 on day 38) mg/kg/day for up to 52 weeks. At all dose levels studied, diclofenac caused ulceration of the gastrointestinal tract. UIceration was confined to the colon in the low-dose &nbsp;group &nbsp;but &nbsp;was present in the stomach and small intestine also in the other two &nbsp;groups. Body weights &nbsp;were below controls. Constipation,&nbsp; with occasional episodes of diarrhea,&nbsp; was a marked feature. In all treated groups, there was a dose-related fall in serum albumin levels. Anemia and an increased ESR were observed in the high-dose group. In the recovery groups (control, low, and intermediate), no intestinal lesions were &nbsp;present. &nbsp;Food &nbsp;consumption &nbsp;and &nbsp;body-weight &nbsp;gains were within normal limits. Hematology parameters were comparable to controls &nbsp;and &nbsp;serum albumin levels returned towards normal values.</p><p>&nbsp;</p><p><strong>Reproduction Studies</strong></p><p>&nbsp;</p><p>Rats: Doses of 2 and 4 mg/kg/day were given orally to male and female rats with no noticeable effect on fertility. Dosing was carried out during premating, mating, gestation, &nbsp;and &nbsp;lactation periods. At the higher dose, prolonged &nbsp;gestation &nbsp;and &nbsp;dystocia &nbsp;were &nbsp;observed. &nbsp;Embryotoxicity (low birth weight, failure to survive) was observed at both doses but it was minimal at 2 mg/kg/day. Post-natal survival and growth of pups from drug-treated animals were comparable to those of controls except for slightly retarded growth at the higher dose.</p><p>&nbsp;</p><p><strong>Mice and Rats:</strong> Teratology studies at oral doses of 2, 3, 10, and 20 mg/kg/day showed no teratogenic effects on fetuses. At the higher doses, pronounced gastrointestinal effects were observed in the dams and a marked toxic effect noted in fetuses (reduced birth weights and increased fetal deaths).</p><p>&nbsp;</p><p><strong>Rabbits: </strong>Pregnant &nbsp;females &nbsp;treated &nbsp;with oral &nbsp;doses of &nbsp;5 or 10 mg/animal/day &nbsp;throughout &nbsp;the gestation&nbsp; &nbsp;period &nbsp;showed &nbsp;a &nbsp;dose-dependent &nbsp;increase &nbsp;in &nbsp;resorption &nbsp;rates, &nbsp;diminished fetus weights, and abnormal skeletal findings Definite &nbsp;embryotoxicity was observed &nbsp;at the highest dose although there was no evidence to suggest teratogenicity.</p><p>&nbsp;</p><p><strong>Mutagenicity Studies</strong></p><p>Mutagenicity studies were carried out <em>in vitro </em>using bacteria with, and without microsomal activation, and in mammalian cells. Studies <em>in vivo </em>were also performed. Diclofenac sodium was not mutagenic in any of these test systems.</p><p>&nbsp;</p><p><strong>Carcinogenicity Studies</strong></p><p>Long-term carcinogenicity studies in rats given diclofenac sodium up to 2 mg/kg/day have revealed no significant increases in tumour incidence. There was a positive &nbsp;dose-related &nbsp;trend with respect to adrenal medullary hyperplasia,&nbsp; mammary &nbsp;fibroadenomas &nbsp;and &nbsp;subcutaneous tissue fibromas in females, as well as of C-cell adenomas of the thyroid &nbsp;in &nbsp;males. &nbsp;The differences in the incidence between the various groups, including control, were small and were considered to reflect the variation in the spontaneous occurrence of these incidental lesions, common in old laboratory rats.</p><p>&nbsp;</p><p>In a 2-year mouse study, only controls and animals at the two lower daily doses of 0.1 and 0.3 mg/kg showed survival sufficient for assessment of carcinogenic potential. The two higher daily doses of 1 and 2 mg/kg resulted in a shortening of lifespan, particularly in males, as a consequence of ulceration and/or perforation of the small intestine and therefore prevented evaluation. The &nbsp;known &nbsp;susceptibility &nbsp;of &nbsp;rodents &nbsp;to &nbsp;non-steroidal &nbsp;anti-inflammatory &nbsp;drugs, resulting in high mortality at dose levels close to the therapeutic dose, is considered to be a rodent-specific effect. Diclofenac sodium was not carcinogenic &nbsp;to mice under the conditions &nbsp;of this study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s) for</strong></p><p><strong>E.C.</strong><strong> </strong><strong>25 &amp; 50 mg</strong></p></td><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s) for</strong></p><p><strong>&nbsp;S.R.<strong> </strong>100 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p>dextrates</p></td><td style="vertical-align:top"><p>dextrates</p></td></tr><tr><td style="vertical-align:top"><p>methylcellulose</p></td><td style="vertical-align:top"><p>microcrystalline cellulose</p></td></tr><tr><td style="vertical-align:top"><p>stearic acid</p></td><td style="vertical-align:top"><p>hydroxyethyl cellulose</p></td></tr><tr><td style="vertical-align:top"><p>magnesium stearate</p></td><td style="vertical-align:top"><p>magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>colloidal silicon dioxide</p></td><td style="vertical-align:top"><p>hydroxypropyl methylcellulose</p></td></tr><tr><td style="vertical-align:top"><p>hydroxypropyl methylcellulose</p></td><td style="vertical-align:top"><p>polyethylene glycol</p></td></tr><tr><td style="vertical-align:top"><p>polyethylene glycol</p></td><td style="vertical-align:top"><p>titanium dioxide</p></td></tr><tr><td style="vertical-align:top"><p>titanium dioxide</p></td><td style="vertical-align:top"><p>red ferric oxide</p></td></tr><tr><td style="vertical-align:top"><p>yellow ferric oxide</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>FD &amp; C yellow #6</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25 mg only (D&amp;C yellow #10)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>polyvinylacetate phthalate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>triethyl citrate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>methanol</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months for 25 & 50 mg and 24 months for 100 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C &amp; protect from high humidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong> Blister</p><p style="margin-left:120px">Film PVC/PVdc Clear 10 MIL 250/60 205 mm</p><p style="margin-left:120px">Foil Silver Plain 205 mm 20&micro;m</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong> Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2014.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>